Загрузка...
Changes in T cell subsets identify responders to FcR non-binding anti-CD3 mAb (teplizumab) in patients with Type 1 diabetes
The mechanisms whereby immune therapies affect progression of Type 1 diabetes (T1D) are not well understood. Teplizumab, an FcR non-binding anti-CD3 mAb, has shown efficacy in multiple randomized clinical trials. We previously reported an increase in the frequency of circulating CD8+ central memory...
Сохранить в:
| Опубликовано в: : | Eur J Immunol |
|---|---|
| Главные авторы: | , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4882099/ https://ncbi.nlm.nih.gov/pubmed/26518356 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/eji.201545708 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|